Pleural disorder

Summary

Pleural disorder (MONDO:0002037) is a disease (an umbrella term covering 5 Mondo subtypes) with 5 GWAS associations across 13 studies and 3 clinical trials. Top therapeutic interventions include porfimer sodium. A subtype of lower respiratory tract disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• GWAS associations: 5
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pleural disorder
Mondo ID	MONDO:0002037
MeSH	D010995
DOID	DOID:1532
NCIT	C26859
SNOMED CT	88075009
UMLS	C0032226
MedGen	10804
Anatomy (UBERON)	UBERON:0000977
Is cancer (heuristic)	no

Also known as: disease of pleura · disease or disorder of pleura · disorder of pleura · non-neoplastic pleural disease · pleura disease · pleura disease or disorder · pleural disorder · pleural disorders

Data availability: 5 GWAS associations (13 studies).

Disease family

This is a subtype of lower respiratory tract disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › pleural disorder

Related subtypes (4): bronchial disorder, tracheal disorder, lung disorder, tracheobronchitis

Subtypes (5): pleurisy, pneumothorax, congenital chylothorax, pleural empyema, pleural neoplasm

Genetics & variants

GWAS landscape

5 GWAS associations across 13 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr9:5073770	7e-12		T	0.99
chr10:103315261	8e-09		C	0.35
chr5:58278906	1e-08		G	1.78
chr8:734105	2e-08		C	1.36
chr11:82048274	4e-08		A	1.48

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90473730	UK Biobank Whole-Genome Sequencing Consortium	2025	22,482	435,958	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667961	UK Biobank Whole-Genome Sequencing Consortium	2025	22,482	435,958	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90473735	UK Biobank Whole-Genome Sequencing Consortium	2025	2,982	455,458	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90080151	Backman JD	2021	1,162	386,480	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084137	Backman JD	2021	1,162	386,480	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90473737	UK Biobank Whole-Genome Sequencing Consortium	2025	920	457,520	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90726965	Kim HI	2026	874	43,152	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90080150	Backman JD	2021	668	387,262	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084136	Backman JD	2021	668	387,262	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90080149	Backman JD	2021	573	387,357	Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	5

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	5

Functional consequences

Consequence	Count
unknown	5

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr9:5073770							7e-12	Tier 4: intronic/intergenic
chr10:103315261							8e-09	Tier 4: intronic/intergenic
chr5:58278906							1e-08	Tier 4: intronic/intergenic
chr8:734105							2e-08	Tier 4: intronic/intergenic
chr11:82048274							4e-08	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07572019	PHASE2/PHASE3	NOT_YET_RECRUITING	Ultrasound Guided Erectror Spinae Block Versus Intracavitary During Medical Thoracoscopy
NCT03678350	PHASE1	COMPLETED	Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
NCT04836429	PHASE1	TERMINATED	Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PORFIMER SODIUM	4	2